For further information
please contact:
Brigitte Stempfer
Tel +49 (0)89 / 32 42 66 111
Send email

Learn more about TRION
and its unique development approach
undefinedCorporate profile

Video, interviews, pictures
and background information
by Fresenius
undefinedMedia information

News Archive

Page 1 Page 2 Next >
September 20, 2011
Fresenius Biotech’s Removab® receives approval for a shorter infusion time in treating malignant ascites – one-year survival rate in Removab®-treated patients is more than four times higher
Read more  Download PDF  
June 20, 2011
ASCO 2011: Fresenius Biotech presents new data for the trifunctional antibody Removab® − benefit in overall survival of cancer patients demonstrated
Read more  Download PDF  
June 06, 2011
Trifunctional Antibody Catumaxomab Triggers Vaccination Effect Against Cancer
Read more  Download PDF  
October 25, 2010
Removab® (Catumaxomab) winner of Galenus-von-Pergamon Prize in the category Specialist Care
Read more    
November 25, 2009
TRION Pharma winner of STEP Award 2009 in the category „Product / Technology“
Read more    
August 25, 2009
TRION among the three finalists nominated for the EUROPEAN BIOTECHNICA AWARD 2009
Read more  Download PDF  
June 02, 2009
Trifunctional Antibody Catumaxomab Kills Cancer Stem Cells
Read more  Download PDF  
April 23, 2009
EU Approval for Removab®: First Trifunctional Antibody Hits Market
Read more  Download PDF  
February 19, 2009
Positive CHMP Opinion for Removab® Validates TRION’s Triomab® Technology
Read more  Download PDF  
April 15, 2008
Highly Effective Elimination of Low Her2 Expressing Tumor Cells by Trifunctional Antibody Ertumaxomab
Read more  Download PDF  
Page 1 Page 2 Next >